Filing Flows › Jazz Pharmaceuticals (JAZZ) › Q1 2025
Jazz Pharmaceuticals (JAZZ) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Jazz Pharmaceuticals (JAZZ) reported revenue of $898M for the first quarter 2025 (Q1 2025), -0.5% from a year earlier and -17% from the quarter before. Operating margin was -6.2%, net loss $92.5M (10.3% of revenue).
Jazz Pharmaceuticals, Q1 2025: revenue $898M (-0.5% year over year), operating margin -6.2%, net loss $92.5M, operating cash flow $430M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $898M | -17% | -0.5% |
| Operating profit | −$55.9M | — | — |
| Net earnings | −$92.5M | — | — |
| Operating cash flow | $430M | +8% | +61% |
| Free cash flow | $416M | +8% | +60% |
What changed
Revenue was $897.8M in Q1 2025, roughly flat year over year and down 17% from the previous quarter. Xywav was the largest line at 38% of revenue. Xyrem lost $27.0M year over year (down 42%), 645% of the total change.
Operating costs exceeded revenue by $55.9M, an operating margin of -6.2%. Total costs grew 14% against flat revenue. The fastest-growing cost line was SG&A (+46%). The quarter ended with a net loss of $92.5M, after a profit of $191.1M the previous quarter. Net interest and other expense of $54.4M was the main reason.
Operating cash flow was $429.8M (up 61% year over year). Non-cash charges added back $164.8M of depreciation and amortization and $67.7M of share-based compensation. Working capital and other items added $289.8M. Capital expenditures of $13.9M left free cash flow of $415.9M.
Questions
What was Jazz Pharmaceuticals' revenue in the first quarter 2025?
Jazz Pharmaceuticals (JAZZ) reported revenue of $898M for the first quarter 2025 (Q1 2025), -0.5% from a year earlier and -17% from the quarter before.
Was Jazz Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $55.9M (-6.2% of revenue) and net loss $92.5M.